Hyporeactivity of ventral striatum towards incentive stimuli in unmedicated depressed patients normalizes after treatment with escitalopram
Abstract
Major Depressive Disorder (MDD) involves deficits in the reward system. While neuroimaging studies have focused on affective stimulus processing, few investigations have directly addressed deficits in the anticipation of incentives. We examined neural responses during gain and loss anticipation in patients with MDD before and after treatment with a selective serotonin reuptake inhibitor (SSRI). Fifteen adults with MDD and 15 healthy participants, matched for age, verbal IQ and smoking habits, were investigated in a functional magnetic resonance imaging (fMRI) study using a monetary incentive delay task. Patients were scanned drug-free and after 6 weeks of open-label treatment with escitalopram; controls were scanned twice at corresponding time points. We compared the blood oxygenation level dependent (BOLD) response during the anticipation of gain and loss with a neutral condition. A repeated measures ANOVA was calculated to identify effects of group (MDD vs. controls), time (first vs. second scan) and group-by-time interaction. Severity of depression was measured with the Hamilton Rating Scale of Depression and the Beck Depression Inventory. MDD patients showed significantly less ventral striatal activation during anticipation of gain and loss compared with controls before, but not after, treatment. There was a significant group-by-time interaction during anticipation of loss in the left ventral striatum due to a signal increase in patients after treatment. Ventral striatal hyporesponsiveness was associated with the severity of depression and in particular anhedonic symptoms. These findings suggest that MDD patients show ventral striatal hyporesponsiveness during incentive cue processing, which normalizes after successful treatment.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
After 6-week treatment with escitalopram, the difference in VS activation during reward anticipation between MDD patients and HCs was no longer measurable.
“After 6-week treatment with escitalopram, this difference was no longer measurable (Stoy et al., 2012).”
From Circuit Mechanisms of Reward, Anhedonia, and Depression (2019) · cites this paper as Stoy et al., 2012
MDD patients exhibit reduced activation of the VS during reward anticipation compared with HCs in an MID task.
“Stoy et al. showed that MDD patients exhibit reduced activation of the VS during reward anticipation compared with HCs in an MID task.”
From Circuit Mechanisms of Reward, Anhedonia, and Depression (2019) · cites this paper as Stoy et al., 2012
The citation lists haven’t been fetched yet
References 69 · Cited by 279
- Authors
- Stoy, M., Schlagenhauf, F., Sterzer, P., Bermpohl, F., Hägele, C., Suchotzki, K., Schmack, K., Wrase, J., Ricken, R., Knutson, B., Adli, M., Bauer, M., Heinz, A., & Ströhle, A.
- Affiliations
- Stiftung Charité (DE)
- Stanford University (US)
- University Hospital Carl Gustav Carus (DE)
- ORCID
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2011-09-17
- Volume
- 26
- Issue
- 5
- Pages
- 677-688
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2106827577
- Cited by
- 279
- References
- 69
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 8 · 2023: 11 · 2022: 37 · 2021: 36 · 2020: 22 · 2019: 19 · 2018: 24 · 2017: 19 · 2016: 23 · 2015: 25 · 2014: 15 · 2013: 17 · 2012: 8
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cognitive Neuroscience › Neural and Behavioral Psychology Studies
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Keywords
- major depressive disorder, ventral striatum, monetary incentive delay task, escitalopram, selective serotonin reuptake inhibitors, anhedonia, depression severity, BOLD signal, antidepressant response
- MeSH terms
- Adult, Basal Ganglia, Major Depressive Disorder, Female, Humans, Magnetic Resonance Imaging, Male, Motivation, Psychiatric Status Rating Scales, Citalopram, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation, Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review